Wire · opportunities
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 July 2026 · Fusion42 review
Arrowhead Pharmaceuticals reported Phase 3 data for plozasiran showing 79-81% triglyceride reduction and 100% acute pancreatitis event reduction in severe hypertriglyceridemia patients, positioning it as potentially best-in-class against Ionis' recently approved Tryngolza. The company plans to file for FDA approval by year-end 2026.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're selling to hypertriglyceridemia patients, two drugs now compete on identical efficacy—the winner will be decided by dosing, administration, and payer coverage, not biology. Start building the distribution and insurance infrastructure now; the clinical race is over.
◆ Coverage
1 source · 22 Jul 2026
◆ Related on Wire
◆ Topics